Incretin-based medications for type 2 diabetes: An overview of reviews

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 649-658

  Gamble, J M ^a   Clarke, A ^a   Myers, K J ^a   Agnew, M D ^a   Hatch, K ^b   Snow, M M ^a   Davis, E M ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Incretin therapy; Systematic review

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TASPOGLUTIDE; TRIACYLGLYCEROL; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CITATION ANALYSIS; CONTROLLED STUDY; DECISION MAKING; DESCRIPTIVE RESEARCH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION; AGONISTS; DIABETES MELLITUS, TYPE 2; LITERATURE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84931957090     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12465     Document Type: Article

References (30)

1. Ranganath LR. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol 2008; 61: 401-409.
2. American Diabetes Association. Standards of medical care in diabetes- 2014. Diabetes Care 2014; 37(Suppl. 1): S14-80.
3. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013; 37(Suppl. 1): S1-212.
5. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008; 117: 574-584.
6. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 2011; 34 (Suppl. 2): S264-271.
7. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012; 109: 1681-1685.
8. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PLoS Med 2007; 4: e78.
9. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 2011; 11: 15.
10. Becker L, Oxman A. Overview of reviews. In: Cochrane Handbook for Systematic Reviews of Interventions Version 510. The Cochrane Collaboration, 2011. (Updated March 2011) [Internet]. Available from URL: www.cochrane-handbook.org.
11. Gamble JM, Conway A, Myers KJ etal. Incretin based drugs for type 2 diabetes: an overview of systematic reviews. PROSPERO 2013; CRD42013005149.
12. Shea BJ, Hamel C, Wells GA etal. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62: 1013-1020.
13. Monasta L, Batty GD, Cattaneo A etal. Early-life determinants of overweight and obesity: a review of systematic reviews: early-life determinants of obesity. Obes Rev 2010; 11: 695-708.
14. Seo H-J, Kim KU. Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers. BMC Med Res Methodol 2012; 12: 129.
15. Jaspers MWM, Smeulers M, Vermeulen H, Peute LW. Effects of clinical decision-support systems on practitioner performance and patient outcomes: a synthesis of high-quality systematic review findings. J Am Med Inform Assoc 2011; 18: 327-334.
16. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; (10): CD006423.
17. Canadian Agency for Drugs and Technologies in Health. CADTH optimal therapy report: second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis. 2010. Available from URL: https://www.cadth.ca/second-and-third-line-therapies-type-2-diabetes. Accessed 7 February 2014
18. Gross JL, Kramer CK, Leitao CB etal. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in Type 2 diabetes: a network meta-analysis. Ann Intern Med 2011; 154: 672-679.
19. Norris SL, Lee NJ, Severance S, Thakurta S, Chan B. Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report. Portland: Oregon Health & Science University, 2008. [Internet] Available from URL: http://www.ncbi.nlm.nih.gov/books/NBK10605/. Accessed 13 April 2014.
20. Jonas D, Van Scoyoc E, Gerrald K etal. Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report. Portland: Oregon Health & Science University, 2011.
21. Norris SL, Kansagara D, Bougatsos C etal. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148: 855-868.
22. Liu S-C, Tu Y-K, Chien M-N, Chien K-L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabet Obes Metab 2012; 14: 810-820.
23. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in Type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011; 45: 850-860.
24. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771.
25. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011; 34: 2474-2476.
26. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3: e0001986.
27. Scirica BM, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
28. White WB, Cannon CP, Heller SR etal. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
29. Oxman AD, Grade Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490-1494.
30. Siontis KC, Hernandez-Boussard T, Ioannidis JPA. Overlapping meta-analyses on the same topic: survey of published studies. BMJ 2013; 347: f4501.